AUTHORS
Monzr M. M Al Malki, MD, Mark B. Juckett, MD, MHCM2, Miguel-Angel Perales, MD3, John Koreth, MD,MBBS,PhD,DPhil4, Yu Kato, PhD5, Janine Powers, PhD6, Mohamed Elgendy, MD7, Marco Londei, MD8, Maria-Grazia Roncarolo, MD9, Filippo Milano I, MD, PhD10
AFFILIATIONS
1 City of Hope Comprehensive Cancer Center, Duarte, California, United States
2 University of Minnesota, Minneapolis, Minnesota, United States
3 Memorial Sloan Kettering Cancer Center, New York, New York, United States
4 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
5 TR1X Bio, San Diego, California, United States
6 TR1X Bio, San Diego, California, United States
7 TR1X Bio, San Diego, California, United States
8 TR1X Bio, San Diego, California, United States
9 TR1X Bio, San Diego, California, United States
10 Fred Hutchinson Cancer Center, Seattle, Washington, United States
ABSTRACT
We conducted a first-in-human, Phase I open-label study (NCT06462365) to assess the safety and tolerability of TRX103 cell product in patients with hematological malignancies undergoing hematopoietic cell transplantation (HCT). Patients received myeloablative conditioning (MAC) or reduced-intensity conditioning (RIC) followed by peripheral blood stem cell (PBSC) transplant from an HLA-mismatched (related, or unrelated) donor. Graft-versus-host disease (GvHD) prophylaxis included post-transplant cyclophosphamide (PTCy), mycophenolate mofetil (MMF) and sirolimus.
In addition to the safety and tolerability primary endpoints, secondary and exploratory endpoints of this Phase I trial include TRX103 pharmacokinetics (PK) and pharmacodynamics (PD), GvHD prevention, overall survival and GvHD relapse free survival (GRFS) at 1-year post-HCT.
Type 1 regulatory T (Tr1) cells are a subset of interleukin-10 (IL-10) producing regulatory T cells (Tregs), with potent anti-inflammatory and immunomodulatory properties. To overcome challenges related to the use of autologous Tr1 Treg cells, Tr1X Inc. has engineered TRX103, a novel off-the-shelf T cell product that mimics the regulatory functions and cytokine secretion profile of naturally occurring Tr1 cells.
TRX103 is generated by transducing CD4+ T cells from healthy donors with a bi-directional lentiviral vector that encodes the human lL-10 gene and a non-signaling truncated form of the human nerve growth factor receptor (ΔNGFR) (M Uyeda et al., Frontiers Immunology, 2026).
Enrollment across all dose cohorts is complete, with patient follow-up and data collection ongoing. Twenty-four adults with high-risk hematological malignancies (AML, B-ALL, MDS, CMML) were enrolled, 13 were transplanted with PBSC from haploidentical donors and 11 from 1/8 or 2/10 HLA mismatched unrelated donors; 9 received MAC and 15 received RIC regimens. Twenty-three patients, evaluable for safety and PK, PD, received the TRX103 cell product across 4 different Dose Levels (DL): DL1=25 × 106, DL2=75 × 106; DL3=225 × 106; and DL4=675 × 106 TRX103 cells.
Safety and tolerability were demonstrated in all patients. No Grade ≥ 3 AEs, serious adverse events (SAEs), or dose-limiting toxicities (DLTs) related to TRX103 infusion were observed at any DL. Three Grades 1-2 TRX103-related AEs were reported at DL3. All patients have engrafted with a median time of neutrophil engraftment of 17 days (range 14-31) and median 100% donor chimerism by day 30 (range 27-42) post-HCT.
A dose-dependent PK of TRX103 was observed, with persistence in peripheral blood for > 21 days and nonlinear exposure at DL3 and DL4. TRX103 cells expanded and maintained their ability to secrete IL-10 in vivo. Post TRX103 infusion patients showed a rapid immune reconstitution with CD4+ T cells reaching >105/ml by day 42 vs. day >100 in historical cohorts of patients receiving PTCy HCT without TRX103 (M Al Malki et al., Blood Advances, 2021; MA Perales et al., Blood Advances, 2025). TRX103 promoted an immune reset with a rapid surge in IL-10 producing tolerogenic dendritic (DC-10) cells followed by an increase in Tr1 Tregs and FOXP3+ Tregs, compared to PTCy HCT historical controls tested in parallel. The tolerogenic immune reset in patients receiving TRX103 was further supported by the demonstration of operational tolerance and induction of donor-derived Tr1 cells specific for the host alloantigens.
Cumulative efficacy data are currently collected and compared to PTCy HCT historical controls, including rate of 100-day grade III-IV acute GHVD, moderate/severe chronic GvHD, nonrelapse mortality, disease-free survival, grade 2,3 infections, GRFS and overall survival.
In conclusion, TRX103 is a novel off-the shelf Tr1 Treg cell product which shows safety and preliminary immunoregulatory properties in HLA-mismatched HCT. Updated data from the Phase I first-in-human study will be presented.
DISCLOSURES
Monzr M. M Al Malki, MD: incyte - Research Funding; gamida cell - Consultancy (Includes expert testimony); Ossium Health - Consultancy (Includes expert testimony); CareDx - Consultancy (Includes expert testimony); Gilead - Consultancy (Includes expert testimony); Jazz Pharma - Consultancy (Includes expert testimony); Tr1x - Consultancy (Includes expert testimony); Tscan Therapeutics - Consultancy (Includes expert testimony)